PE20030731A1 - Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii - Google Patents

Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii

Info

Publication number
PE20030731A1
PE20030731A1 PE2003000052A PE2003000052A PE20030731A1 PE 20030731 A1 PE20030731 A1 PE 20030731A1 PE 2003000052 A PE2003000052 A PE 2003000052A PE 2003000052 A PE2003000052 A PE 2003000052A PE 20030731 A1 PE20030731 A1 PE 20030731A1
Authority
PE
Peru
Prior art keywords
composition
basic amino
acid
amino acids
refers
Prior art date
Application number
PE2003000052A
Other languages
English (en)
Inventor
Wolfram Ledwoch
Felix Ecker
Ralf Bullesbach
Gerhard Franckowiak
Uwe Gessner
Marianne Petersen-Braun
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20030731A1 publication Critical patent/PE20030731A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: i)UNA SAL DE ACIDO O-ACETILSALICILICO; ii)UN AMINOACIDO BASICO, TAL COMO LISINA, ARGININA, HISTIDINA, ORNITINA O ACIDO DIAMINOBUTIRICO, QUE PRESENTA UN TAMANO MEDIO DE GRANO SUPERIOR A UN TAMANO DE GRANO DE 160 µm Y UNA PROPORCION DE MAS DE 60% DE LAS PARTICULAS CON UN TAMANO DE GRANO EN UN INTERVALO DE 100 µm A 200 µm; Y, iii)UN AGENTE DE FLUENCIA TAL COMO UNO O MAS SACARIDOS, SELECCIONADOS DE MANITOL, SORBITOL, XILITOL Y LACTOSA ASI COMO SUS MEZCLAS. DONDE LA COMPOSICION ESTA GRANULADA EN SECO, PREFERIBLEMENTE COMPACTADA ENTRE RODILLOS. SE REFIERE TAMBIEN A MEDICAMENTOS QUE CONTIENEN DICHA COMPOSICION Y AL USO DE LA MISMA EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES CARDIACAS ISQUEMICAS, APOPLEJIA CEREBRAL, ANGINA DE PECHO, INFARTO DE MIOCARDIO Y SIMILARES
PE2003000052A 2002-01-18 2003-01-17 Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii PE20030731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10202019A DE10202019A1 (de) 2002-01-18 2002-01-18 Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II

Publications (1)

Publication Number Publication Date
PE20030731A1 true PE20030731A1 (es) 2003-09-22

Family

ID=7712593

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000052A PE20030731A1 (es) 2002-01-18 2003-01-17 Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii

Country Status (31)

Country Link
US (1) US20050171070A1 (es)
EP (1) EP1469835B1 (es)
JP (1) JP2005519892A (es)
KR (1) KR20040079936A (es)
CN (1) CN1298314C (es)
AR (1) AR038298A1 (es)
AT (1) ATE378040T1 (es)
AU (1) AU2003235700B2 (es)
BR (1) BR0307009A (es)
CA (1) CA2473893A1 (es)
CO (1) CO5611102A2 (es)
CU (1) CU20040161A7 (es)
DE (2) DE10202019A1 (es)
EC (1) ECSP045192A (es)
ES (1) ES2297166T3 (es)
GT (1) GT200300004A (es)
HK (1) HK1080371A1 (es)
HN (1) HN2003000015A (es)
HR (1) HRP20040742B1 (es)
IL (1) IL162881A0 (es)
MX (1) MXPA04006832A (es)
NO (1) NO20043404L (es)
NZ (1) NZ534128A (es)
PE (1) PE20030731A1 (es)
PL (1) PL370197A1 (es)
RS (1) RS63804A (es)
SV (1) SV2004001457A (es)
TW (1) TWI265810B (es)
UY (1) UY27612A1 (es)
WO (1) WO2003059323A2 (es)
ZA (1) ZA200405533B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025535A1 (de) * 2004-05-25 2005-12-22 Bayer Healthcare Ag Kombination von Salzen der o-Acetylsalicylsäure und Alpha-Glucosidase-Inhibitoren
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
DE102008004386A1 (de) * 2008-01-14 2009-07-23 Activaero Gmbh Verwendung eines Acetylsalicylsäuresalzes zur Behandlung viraler Infektionen
JP5309977B2 (ja) * 2008-12-26 2013-10-09 ライオン株式会社 チュアブル錠
US8173625B2 (en) * 2009-05-08 2012-05-08 Theaprin Pharmaceuticals Inc. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
BRPI1009600A2 (es) * 2009-06-25 2016-03-22 Tetra S A
JP5563835B2 (ja) * 2010-01-15 2014-07-30 全星薬品工業株式会社 アスピリン錠剤の製造方法
ITMI20121144A1 (it) * 2012-06-28 2013-12-29 Dipharma Francis Srl Procedimento per la preparazione di un sale di un farmaco antinfiammatorio non steroideo
US10882811B2 (en) 2016-12-23 2021-01-05 Aspiair Gmbh Synthesis of lysine acetylsalicylate glycine particles
RU2738831C1 (ru) * 2020-03-03 2020-12-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ консервативного лечения невралгии тройничного нерва

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
FR2611501B1 (fr) * 1987-03-04 1991-12-06 Corbiere Jerome Nouvelles compositions pharmaceutiques pour la voie buccale a base d'acetylsalielylate de lysine et leur procede d'obtention
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren

Also Published As

Publication number Publication date
HK1080371A1 (en) 2006-04-28
CO5611102A2 (es) 2006-02-28
TWI265810B (en) 2006-11-11
AU2003235700A1 (en) 2003-07-30
UY27612A1 (es) 2003-08-29
CN1298314C (zh) 2007-02-07
SV2004001457A (es) 2004-05-07
CU20040161A7 (es) 2007-03-23
ECSP045192A (es) 2004-08-27
PL370197A1 (en) 2005-05-16
IL162881A0 (en) 2005-11-20
DE50308596D1 (de) 2007-12-27
ZA200405533B (en) 2005-07-13
JP2005519892A (ja) 2005-07-07
DE10202019A1 (de) 2003-07-24
RS63804A (en) 2006-12-15
BR0307009A (pt) 2004-11-03
HRP20040742B1 (en) 2008-05-31
US20050171070A1 (en) 2005-08-04
HRP20040742A2 (en) 2005-08-31
TW200306199A (en) 2003-11-16
EP1469835B1 (de) 2007-11-14
GT200300004A (es) 2003-08-22
MXPA04006832A (es) 2004-12-06
NZ534128A (en) 2005-08-26
ES2297166T3 (es) 2008-05-01
WO2003059323A2 (de) 2003-07-24
CA2473893A1 (en) 2003-07-24
HN2003000015A (es) 2003-08-22
EP1469835A2 (de) 2004-10-27
AR038298A1 (es) 2005-01-12
ATE378040T1 (de) 2007-11-15
NO20043404L (no) 2004-08-16
AU2003235700B2 (en) 2007-06-28
CN1642528A (zh) 2005-07-20
WO2003059323A3 (de) 2004-03-11
KR20040079936A (ko) 2004-09-16

Similar Documents

Publication Publication Date Title
PE20030731A1 (es) Sales estables del acido o-acetilsalicilico con aminoacidos basicos ii
Paschen et al. Polyamine changes in reversible cerebral ischemia
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
ES2075011T3 (es) Uso de sales del acido gamma-hidroxibutirico para preparar composiciones farmaceuticas para uso en el tratamiento del alcoholismo, y las composiciones obtenidas.
DE502005008880D1 (de) Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE66998A1 (es) Composiciones para el tratamiento con una dosis diaria para enfermedades producidas por la ciclooxigenasa-2
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
CO6290632A2 (es) Composición oral que contiene péptidos y proteasas
PE20061046A1 (es) Composicion farmaceutica que comprende telmisartan y amlodipino
CO4340618A1 (es) Composicion farmaceutica para liberacion controlada
SE0200979D0 (sv) New compounds
AR015493A1 (es) DERIVADOS CICLOHEXILOS , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA COMPOSICIoN uTIL PARA INHIBIR LA ACTIVIDAD IN VITRO DE NEURAMINIDASA Y PARA EL TRATAMIENTO O PROFILAXIS DE LA INFECCIoN DE INFLUENZA Y PARA TRATAIMIENTO, Y UN MÉTODO IN VITRO PARA INHIBIR LA ACTIVI
AR030305A1 (es) Composicion que comprende sales de acido o-acetilsalicilico con aminoacidos basicos, un procedimiento para su preparacion, uso de dicha composicion para la manufactura de un medicamento
ECSP034848A (es) Derivados oxazol acido carboxilico sustituidos para uso como activadores ppar-alpha y -gamma en el tratamiento de diabetes
IL171987A0 (en) The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
ES2165936T3 (es) Procedimiento para la fabricacion de una formulacion terapeutica liposomal seca y solida, dispersable en agua, de administracion oral.
HUP0002932A2 (hu) HIV-proteáz inhibitorokat tartalmazó gyógyszerkészítmények
NL194390B (nl) Farmaceutische samenstelling die analgetische activiteit bezit met (s)- 2-(6-methoxy-2-naftyl)propionzuur en arginine.
AR038144A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
AR050363A1 (es) Liofilizado de modafinil oral
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
PE20001496A1 (es) Formulacion de liberacion controlada para el tratamiento de epoc
CO5611150A2 (es) Formulacion en aerosol de una sal de tiotropio de administracion directa para inhalacion
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen

Legal Events

Date Code Title Description
FC Refusal